Anti-IL13 receptor alpha-2 chimeric antigen receptor T cell therapy - Juno Therapeutics

Drug Profile

Anti-IL13 receptor alpha-2 chimeric antigen receptor T cell therapy - Juno Therapeutics

Alternative Names: Anti-interleukin13 receptor alpha-2 CAR-T cell therapy - Juno Therapeutics; CAR T cell therapy targeting il13 receptor alpha-2 - Juno Therapeutics; IL13rα2 CAR-T cell therapy - Juno Therapeutics

Latest Information Update: 23 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Interleukin 13 receptor alpha2 subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioblastoma

Most Recent Events

  • 23 Mar 2017 Juno Therapeutics plans a phase I trial for Glioblastoma in USA
  • 01 Mar 2017 Preclinical trials in Glioblastoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top